TY - JOUR
T1 - Epilepsy
T2 - New advances
AU - Moshé, Solomon L.
AU - Perucca, Emilio
AU - Ryvlin, Philippe
AU - Tomson, Torbjörn
N1 - Funding Information:
SLM is an employee of the Einstein College of Medicine and Charles Frost Chair in Neurosurgery and Neurology. He received grants from the US National Institutes of Neurological Diseases and Stroke (NINDS: NS-20253, NS-43209, NS-45911, NS-78333) and from the US Department of Defense, CURE Foundation, UCB Pharma, the Heffer Family Medical Foundation and the Segal Family Foundation. He received consultancy fees from Lundbeck and UCB Pharma. EP is an employee of the University of Pavia and received grants from the European Union, the Italian Medicines Agency, the Italian Ministry of Health, the Italian Ministry for Education, University and Research and the C Mondino National Neurological Institute. He also received speaker's or consultancy fees from GW Pharma, Upsher-Smith, Eisai, GSK, Lundbeck, Medichem, Sun Pharma, Supernus, UCB Pharma, Vertex, and Viropharma. PR is an employee of the University Claude Bernard Lyon-1 and Hospices Civils de Lyon, and received grants from the European Union, the French Ministry of Health (PHRC), and the French Agency for Research (ANR). He also received speaker's or consultancy fees from Eisai, GSK, UCB Pharma, Cyberonics, and Medtronic. TT is an employee of Karolinska Institutet and received grants from Stockholm County Council, AFA Insurance, CURE, GSK, Eisai, UCB, Sanofi-Aventis, Novartis, and Bial. He has received speaker's or consultancy fees from Eisai, GSK, UCB, and Sun Pharma.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/3/7
Y1 - 2015/3/7
N2 - Summary Epilepsy affects 65 million people worldwide and entails a major burden in seizure-related disability, mortality, comorbidities, stigma, and costs. In the past decade, important advances have been made in the understanding of the pathophysiological mechanisms of the disease and factors affecting its prognosis. These advances have translated into new conceptual and operational definitions of epilepsy in addition to revised criteria and terminology for its diagnosis and classification. Although the number of available antiepileptic drugs has increased substantially during the past 20 years, about a third of patients remain resistant to medical treatment. Despite improved effectiveness of surgical procedures, with more than half of operated patients achieving long-term freedom from seizures, epilepsy surgery is still done in a small subset of drug-resistant patients. The lives of most people with epilepsy continue to be adversely affected by gaps in knowledge, diagnosis, treatment, advocacy, education, legislation, and research. Concerted actions to address these challenges are urgently needed.
AB - Summary Epilepsy affects 65 million people worldwide and entails a major burden in seizure-related disability, mortality, comorbidities, stigma, and costs. In the past decade, important advances have been made in the understanding of the pathophysiological mechanisms of the disease and factors affecting its prognosis. These advances have translated into new conceptual and operational definitions of epilepsy in addition to revised criteria and terminology for its diagnosis and classification. Although the number of available antiepileptic drugs has increased substantially during the past 20 years, about a third of patients remain resistant to medical treatment. Despite improved effectiveness of surgical procedures, with more than half of operated patients achieving long-term freedom from seizures, epilepsy surgery is still done in a small subset of drug-resistant patients. The lives of most people with epilepsy continue to be adversely affected by gaps in knowledge, diagnosis, treatment, advocacy, education, legislation, and research. Concerted actions to address these challenges are urgently needed.
UR - http://www.scopus.com/inward/record.url?scp=84924128158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924128158&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(14)60456-6
DO - 10.1016/S0140-6736(14)60456-6
M3 - Review article
C2 - 25260236
AN - SCOPUS:84924128158
SN - 0140-6736
VL - 385
SP - 884
EP - 898
JO - The Lancet
JF - The Lancet
IS - 9971
ER -